

# ANDERS HÄRFSTRAND

Executive leader in the pharmaceutical industry, M.D., Ph.D.



## Description

Sustained global track record of success in building commercial operations, global marketing management product development.

34 years of significant global experience in leading and managing change through the course of organizational growth, restructuring and multiple mergers (7) at corporate executive management as well as country levels.

Experience as member of the Board of Directors of private and public Swiss and International Companies including the NASDAQ listed Prothena Inc, Vivesto (former chairman), and Diurnal Group (chairman).

Significant experience in financing, re-financing and BD/M&A operations.

<b>Professional background</b>	2010 -	Härfstrand Consulting AG	Founder
	Sep 2014 - Jan 2015	BBB Therapeutics	Chief Executive Officer
	Jan 2013 - Jul 2014	Makhteshim Agan Europe	Chief Executive Officer
	May 2011 - Dec 2012	Humabs Biomed SA	President & Chief Executive Officer
	Aug 2007 - Apr 2010	Nitec Pharma AG	Chief Executive Officer
	May 2006 - Jul 2007	Serono International	Senior Executive Vice President
	Jun 2005 - May 2006	Serono Geneva	Senior Vice President Corporate Marketing
	2003 - Apr 2005	Pfizer Japan	Executive Vice President
	1988 - 2003	Pfizer/Pharmacia	Vice President, Corporate Executive, Member of the Executive Board, Head of Several TAs World Wide

<b>Educational background</b>	1987	Karolinska Institutet, Sweden	Doctor of Medical Science (Ph.D)
	1983	Karolinska Institutet, Sweden	Medical Doctor (M.D)
	1976	Beskowska Skolan, Stockholm	

## Certifications and training

2007	Chartered Director Program Institute of Directors, London
2003	Pfizer Executive Leadership Development Program Harvard Business School, Boston
1995-1999	Internal program at Pharmacia & Upjohn
1988-1991	Dynargie Leadership Training Sweden
1991	Executive Management School International School of Business Management, IFL, Stockholm

<b>Current board positions</b>	Since 2021	Diurnal Group (LON: DNL)	Chairman of the Board of Directors
	Since 2015	Prothena (NASDAQ: PRTA)	Member of the Board of Directors
	Since 2010	Härfstrand Consulting AG	Chairman

# JOHAN LUTHMAN

## EVP & Head R&D, Lundbeck



### Description

30 years' experience of pharmaceutical industry research and development. Experience with R&D management, project & portfolio management.

Pharmaceutical R&D management experience leading sections, departments, R&D sites and Global R&D functions (up to ~ 1000 FTEs organizations).

Experience in initiating and managing numerous novel drug discovery projects and experience in directing multiple preclinical development projects into phase 1 studies.

Extensive experience in leading several development projects through phase IIB (PoC) studies, and phase III programs, including numerous regulatory submissions (INDs/CTAs, etc.) and approvals of several drugs (~20 NDA, sNDA, MAAs etc.)

Involved as leading manager in numerous Pharma and Biotech partnerships and M&A activities. Also engaged in some major Pharma-Diagnostics company partnerships for device and companion diagnostics developments.

### Professional background

Feb 2019 -	Lundbeck	EVP & Head R&D
Nov 2018 - Feb 2019	Eisai US	SVP & Head Clinical Development, NBG
Jan 2014 - Nov 2018	Eisai US	VP & Head Clinical Development, NBG
Feb 2011 - Dec 2013	Merck	Senior Program Leader, Neuroscience & R&D
Aug 2009 - Feb 2011	Merck	VP & Franchise Integrator, Neuroscience
Feb 2009 - Aug 2009	GeNeuro	CEO
May 2008 - Jan 2009	Merck Serono	Global Head Experimental Medicine Neurology
Jan 2007 - May 2008	Serono/Merck Serono	SVP & Therapy Area Head Neurology, Immunology and Inflammation R&D
1991 - 2005	Astra/AstraZeneca	Director & Head Preclinical and Translational Medicine
1989 - 1991	Colorado University	Regular Fellow, Psychiatry and Pharmacology
1980 - 1988	Karolinska Institutet	Teaching assistant and doctoral research

### Educational background

2002	University of Chile, Santiago	Honorary Professor in Pharmacology
1993	Karolinska Institutet, Sweden	Associate Professor in Neurobiology and Cell Biology
1989	Karolinska Institutet, Sweden	Ph. D. in Neurobiology and Histology
1984	Karolinska Institutet, Sweden	Doctor in Dental Sciences (D.D.S)

### Certifications and training

2006	<b>Serono Business Leadership Program</b> held by Thunderbird and MIT/Sloan Management
2001	<b>Managing Medical Product Innovation: The European Medical Product Executive Program</b> Scandinavian International Management Institute (SIMI)
1997	<b>Taking the Lead in R&amp;D Programme</b> Astra, Sweden

# BETÜL SUSAMIS UNARAN

Chief Strategy and Digital Officer, Zur Rose Group



## Description

Highly accomplished leader with strategic agility, entrepreneurial mindset, interpersonal savvy and diversified deep international operational experience.

Cross-cultural and cross-functional leadership with demonstrated expertise to build successful businesses and strong teams, to lead impactful turnaround, digital and commercial transformation programs, and make things happen.

Strong passion for data and digital. Leading innovative first-of-its-kind digital initiatives with speed, scale and impact' to transform lives of people and disrupt healthcare outcomes.

Recognized for strong business acumen, customer focus, energy and drive for impact. Selected as one of the Top 10 Future Shapers by Handelszeitung and Global Top CDO 100 2022 by HotTopics.ht and Hewlett Packard Ent.

## Professional background

Nov 2019 -	Zur Rose Group (Switzerland)	Chief Strategy and Digital Officer
2018 - Nov 2019	Novartis Pharmaceuticals (Switzerland)	Global Head of Digital Medicines
2016 - 2017	Ferring Pharmaceuticals (Switzerland)	Global Head of Digital
2012 - 2016	Ferring Pharmaceuticals (Switzerland)	Director of Global Operations
2004 - 2012	McKinsey & Company (Switzerland & UK)	Senior Consultant
2001 - 2003	Procter & Gamble (Turkey)	Category Finance Manager
1999 - 2001	Procter & Gamble (Germany)	Internal Consultant

## Educational background

2003 - 2004	INSEAD	MBA Programme (Dean's List)
1994 - 1999	Bogazici University	BS in Industrial Engineering (High Honors)

## Board positions

Since 2021	Ypsomed (Switzerland)	Member of Board of Directors
Since 2020	Arsenal Capital Partners (US)	Advisory Board Member
2019 - 2021	Native Design (UK & US)	Advisory Board Member